The estimated Net Worth of Bros. Advisors Lp Baker Bro... is at least $7.3 millió dollars as of 23 April 2019. Bros Bro owns over 892,857 units of Atreca Inc stock worth over $73,866 and over the last 9 years Bros sold BCEL stock worth over $7,222,027.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Bros Bro BCEL stock SEC Form 4 insiders trading
Bros has made over 11 trades of the Atreca Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Bros bought 892,857 units of BCEL stock worth $12,499,998 on 23 April 2019.
The largest trade Bros's ever made was buying 2,783,605 units of Atreca Inc stock on 20 September 2016 worth over $34,099,161. On average, Bros trades about 579,809 units every 73 days since 2015. As of 23 April 2019 Bros still owns at least 820,729 units of Atreca Inc stock.
You can see the complete history of Bros Bro stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Atreca Inc
Over the last 5 years, insiders at Atreca Inc have traded over $4,571,843 worth of Atreca Inc stock and bought 6,001 units worth $76,740 . The most active insiders traders include Group, Llc Green Jeremy Red..., Bros. Advisors Lp Baker Bro... és Harbor Master Investors (Ca.... On average, Atreca Inc executives and independent directors trade stock every 20 days with the average trade being worth of $991. The most recent stock trade was executed by John A Orwin on 11 April 2024, trading 1 units of BCEL stock currently worth $0.
What does Atreca Inc do?
atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics. with its immune repertoire capture™ (irc™) technology, atreca has an unparalleled insight into how cancer patients’ immune responses can drive better clinical outcomes. atreca was founded by scientists, industry experts, and investors who share the vision that unlocking the immune response of today’s patients is the key to creating a new generation of therapies. atreca is looking for talented, entrepreneurial people who are dedicated to making a positive impact on human health. if you are interested in becoming part of the atreca team, our open positions can be found at: http://www.atreca.com/careers/
What does Atreca Inc's logo look like?
Complete history of Bros Bro stock trades at Bellicum Pharmaceuticals Inc, Idera Pharmaceuticals, Mirati Therapeutics Inc, Invitae Corp, Rhythm Pharmaceuticals, Hookipa Pharma Inc és Atreca Inc
Atreca Inc executives and stock owners
Atreca Inc executives and other stock owners filed with the SEC include:
-
John A. Orwin,
Pres, CEO & Director -
Herbert C. Cross,
Chief Financial Officer -
Dr. Stephen Gould Ph.D.,
Chief Scientific Officer -
Dr. Jonathan Benjamin M.D., Ph.D.,
Sr. VP of Clinical Research -
Dr. Daniel Emerling,
Sr. VP of Research -
Courtney J. Phillips J.D.,
Gen. Counsel & Corp. Sec. -
Dr. Yann Chong Tan,
Chief Technologist -
Dr. Tito A. Serafini Ph.D.,
Founder, Chief Strategy Officer & Director -
Bros. Advisors Lpbaker Juli...,
-
Kristine M Ball,
Director -
David L. Lacey,
Director -
Philippe C Bishop,
Chief Medical Officer -
Tito Serafini,
-
Franklin M Berger,
Director -
Brian G Atwood,
Director -
Lawrence Steinman,
Director -
William Hewitt Robinson,
Director -
& Melinda Gates Foundation ...,
-
Group, Llc Green Jeremy Red...,
-
Harbor Master Investors (Ca...,
10% owner -
Bros. Advisors Lp Baker Bro...,
-
Guy Cavet,
Chief Technical Officer -
Norman Michael Greenberg,
Chief Scientific Officer -
Lindsey Rolfe,
Director -
Herb Cross,
Chief Financial Officer -
Lisa Lynn Decker,
Chief Business Officer -
Stacey Ma,
Director -
Stephen R Brady,
Director -
Stephen E Gould,
Chief Scientific Officer -
Phillips Courtney,
GENERAL COUNSEL & SECRETARY -
John A Orwin,
PRESIDENT & CEO